KLP Kapitalforvaltning AS Purchases Shares of 11,800 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

KLP Kapitalforvaltning AS purchased a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) in the 4th quarter, Holdings Channel reports. The institutional investor purchased 11,800 shares of the company’s stock, valued at approximately $150,000.

A number of other hedge funds also recently bought and sold shares of DAWN. Frazier Life Sciences Management L.P. bought a new position in shares of Day One Biopharmaceuticals in the 3rd quarter worth approximately $9,607,000. Wellington Management Group LLP grew its stake in shares of Day One Biopharmaceuticals by 142.1% during the 3rd quarter. Wellington Management Group LLP now owns 721,581 shares of the company’s stock valued at $10,052,000 after purchasing an additional 423,543 shares during the period. Geode Capital Management LLC raised its position in Day One Biopharmaceuticals by 10.5% in the third quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company’s stock worth $19,961,000 after acquiring an additional 136,458 shares during the period. Jackson Creek Investment Advisors LLC bought a new stake in Day One Biopharmaceuticals during the fourth quarter valued at about $1,313,000. Finally, Franklin Resources Inc. raised its stake in Day One Biopharmaceuticals by 2.3% during the 3rd quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company’s stock worth $55,336,000 after acquiring an additional 87,262 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Bank of America dropped their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. JPMorgan Chase & Co. decreased their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Wedbush reaffirmed an “outperform” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $32.29.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares of the company’s stock, valued at $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the sale, the general counsel now directly owns 39,602 shares in the company, valued at $473,639.92. This represents a 10.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,064 shares of company stock worth $251,925. Insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $6.71 on Wednesday. The business’s 50-day moving average is $9.76 and its 200 day moving average is $12.23. The firm has a market capitalization of $680.09 million, a P/E ratio of -6.51 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a 1 year low of $6.65 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to analyst estimates of $27.11 million. On average, analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.